Nimesulida Ciclum (Nimesulide)

Nimesulide, the active ingredient in Nimesulida Ciclum, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral formulation for oral use. It is employed to relieve mild to moderate pain and to reduce inflammation in conditions such as osteoarthritis and dysmenorrhea, primarily in adult patients. It is indicated for short‑term management of pain and inflammation, and is available only by prescription in the European market.

GNH USA supplies Nimesulida Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks across Europe, Asia and the Americas.

Nimesulide acts as an NSAID to alleviate pain and inflammation in musculoskeletal and gynecologic conditions.

- Mild to moderate pain: Provides analgesic relief for acute or chronic pain of various origins. - Osteoarthritis: Reduces joint inflammation and improves functional mobility in adults with osteoarthritis. - Dysmenorrhea: Alleviates menstrual pain by decreasing uterine prostaglandin production. - Post‑operative pain: Assists in managing pain after minor surgical procedures.

Nimesulide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Skin rash: mild erythema or pruritus. - Diarrhoea: loose stools. - Mouth ulcers: minor aphthous lesions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: acute kidney injury or reduced renal function. - Blood dyscrasias: neutropenia or thrombocytopenia. - Allergic anaphylaxis: rapid onset of respiratory distress and hypotension.

When prescribing Nimesulide, clinicians should consider several precautionary measures to minimise risk.

- Assess liver function: baseline hepatic enzymes should be evaluated before initiating therapy. - Monitor renal status: avoid use in patients with severe renal impairment or dehydration. - Limit duration: restrict treatment to the shortest effective period, typically not exceeding 15 days. - Avoid in ulcer history: contraindicated in patients with active peptic ulcer disease or gastrointestinal bleeding. - Caution with anticoagulants: may increase bleeding risk when combined with warfarin or other anticoagulants. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Nimesulide can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal and renal toxicity. - Lithium: reduced renal clearance may raise lithium levels.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, diuretics): possible reduction in antihypertensive effect. - Methotrexate: decreased renal elimination may enhance toxicity. - Corticosteroids: heightened risk of gastrointestinal ulceration.